Literature DB >> 23428306

Components of the interleukin-6 transsignalling system are associated with the metabolic syndrome, endothelial dysfunction and arterial stiffness.

Thomas W Weiss1, Harald Arnesen, Ingebjorg Seljeflot.   

Abstract

OBJECTIVE: The metabolic syndrome (MetS) is an increasing epidemiologic challenge and cardiovascular risk factor. Interleukin-6 (IL-6) is a cytokine that exerts its biological function via a complex orchestration of soluble and membrane bound receptors. We have investigated associations between IL-6 and its soluble receptors, soluble IL-6 receptor (sIL-6r) and soluble glycoprotein 130 (sGP130) and the metabolic syndrome. Furthermore, we have investigated possible associations with endothelial dysfunction and arterial stiffness.
METHODS: A total of 563 subjects were included in this study. The Adult Treatment Panel III criteria of the National Cholesterol Education Program were used for the definition of MetS. We used commercially available ELISA to analyse circulating levels of the markers. Pulse wave propagation time (PWP) was determined to assess arterial stiffness.
RESULTS: The criteria for having MetS were filled by 221 subjects. sGP130, sIL-6r and IL-6 levels were elevated in subjects with MetS (p<0.05 for all markers), and are associated with increasing components of MetS. Particularly hypertriglyceridaemia, hypertension and fasting plasma glucose (FPG) seem to carry this association. sGP130 (p<0.01), IL-6 (p<0.05) and partially sIL-6r (p<0.05) correlated with markers of endothelial function (E-selectin, I-CAM-1, V-CAM-1) and inversely with PWP after adjustment for relevant covariates.
CONCLUSION: sGP130, sIL-6r and IL-6 were significantly elevated in subjects with MetS. In addition, sGP130, IL-6 and partially sIL-6r were associated with markers of endothelial function and arterial stiffness. This finding sheds new light on the role of these inflammatory cytokines in subjects with MetS and the development and progression of clinically silent atherosclerosis.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23428306     DOI: 10.1016/j.metabol.2013.01.019

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  36 in total

Review 1.  Understanding the Role of the Gut Microbiome and Microbial Metabolites in Obesity and Obesity-Associated Metabolic Disorders: Current Evidence and Perspectives.

Authors:  Natalia Vallianou; Theodora Stratigou; Gerasimos Socrates Christodoulatos; Maria Dalamaga
Journal:  Curr Obes Rep       Date:  2019-09

2.  The effects of vitamin D supplementation on proatherogenic inflammatory markers and carotid intima media thickness in subjects with metabolic syndrome: a randomized double-blind placebo-controlled clinical trial.

Authors:  Shabnam Salekzamani; Abolhassan Shakeri Bavil; Hossein Mehralizadeh; Mohammad Asghari Jafarabadi; Aymaral Ghezel; Bahram Pourghassem Gargari
Journal:  Endocrine       Date:  2017-05-16       Impact factor: 3.633

3.  Cytokine, Chemokine, and Cytokine Receptor Changes Are Associated With Metabolic Improvements After Bariatric Surgery.

Authors:  Risa M Wolf; Andrew E Jaffe; Kimberley E Steele; Michael A Schweitzer; Thomas H Magnuson; Andrew Wolfe; G William Wong
Journal:  J Clin Endocrinol Metab       Date:  2019-03-01       Impact factor: 5.958

4.  Metabolic Syndrome, Physical Activity, and Inflammation: A Cross-Sectional Analysis of 110 Circulating Biomarkers in Japanese Adults.

Authors:  Sarah C Van Alsten; Charles S Rabkin; Norie Sawada; Taichi Shimazu; Hadrien Charvat; Taiki Yamaji; Manami Inoue; Troy J Kemp; Ligia A Pinto; M Constanza Camargo; Shoichiro Tsugane; Minkyo Song
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2020-05-28       Impact factor: 4.254

5.  Changes in interleukin-6 tear concentration and clinical outcome in moderate-to-severe bacterial corneal ulcers after corneal collagen cross-linking.

Authors:  Marzarendra Dhion Erlangga; Indra Tri Mahayana; Jajah Fachiroh; Angela Nurini Agni; Agus Supartoto; Suhardjo Pawiroranu
Journal:  Int J Ophthalmol       Date:  2018-08-18       Impact factor: 1.779

6.  Pre-diabetes in overweight youth and early atherogenic risk.

Authors:  Stephen F Burns; SoJung Lee; Fida Bacha; Hala Tfayli; Tamara S Hannon; Silva A Arslanian
Journal:  Metabolism       Date:  2014-08-27       Impact factor: 8.694

7.  Interleukin-6, soluble interleukin-6 receptor/interleukin-6 complex and insulin resistance in obese children and adolescents.

Authors:  G De Filippo; D Rendina; F Moccia; V Rocco; A Campanozzi
Journal:  J Endocrinol Invest       Date:  2014-09-23       Impact factor: 4.256

8.  Pharmacological concentrations of irisin increase cell proliferation without influencing markers of neurite outgrowth and synaptogenesis in mouse H19-7 hippocampal cell lines.

Authors:  Hyun-Seuk Moon; Fadime Dincer; Christos S Mantzoros
Journal:  Metabolism       Date:  2013-05-07       Impact factor: 8.694

Review 9.  IL-6 in diabetes and cardiovascular complications.

Authors:  Dan Qu; Jian Liu; Chi Wai Lau; Yu Huang
Journal:  Br J Pharmacol       Date:  2014-08       Impact factor: 8.739

10.  IL-6 signalling in patients with acute ST-elevation myocardial infarction.

Authors:  Vibeke N Ritschel; Ingebjørg Seljeflot; Harald Arnesen; Sigrun Halvorsen; Thomas Weiss; Jan Eritsland; Geir Ø Andersen
Journal:  Results Immunol       Date:  2013-12-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.